Small Cap Feast

1st March 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
Hamak Gold (HAMA.L) has today been admitted to a Standard Listing and to trading on the Main Market. Hamak Gold’s strategy focuses on exploration in highly prospective and under-explored areas of Liberia targeting hard rock sources of gold. The Company holds two priority gold exploration licences, Nimba and Gozohn, with an option over five more licences (Lofa, Fasama, Cestos, Sinoe and River Gee), covering a combined area of 4,965 square kilometers. No funds raised.
Off The Menu:
No Leavers Today.

What’s Cooking In The IPO Kitchen?

More Acquisitions plc, a new type of special purpose acquisition company, intends to list on the Main Market. Raising approximately £1.2m. Due 4th March 2022.

Majestic Corporation plc, to join AQSE Growth Market. Majestic is a profitable business recycling precious and non-ferrous metals from obsolete mechanical and industrial material including catalytic convertors, printed circuit boards, legacy electrical and electronic equipment, and industrial metal residues left over from manufacturing. The metals extracted for recycling include gold, platinum, rhodium and palladium. The company uses a network of partners to source, acquire, store, and process material and once the waste precious metal is ready it is supplied to refineries, in countries such as Japan, for reconstitution and resupply in to the global supply chain. Due 2 March 2022.

Shellraise plc, to join AQSE Growth Market. The Company will focus on identifying investment opportunities in companies operating in the viticulture sector which require funding to increase output. Mkt Cap and Capital to be raised TBC. Expected 4 March 2022.

Invinity Energy Systems plc, intends to join AQSE Growth Market. The AIM listed Company (IES.L) manufactures flow batteries for large-scale, high-throughput energy storage requirements of business, industry and electrical networks.

URA Holdings, a London based mining exploration and development company, intends to list on the Main Market (Standard). URA, a former AIM-listed company, is refinanced and ready for listing as an African focused mineral exploration company. The Company’s purpose is to seek unique, value-enhancing opportunities in minerals as a project generator including to prove-up early-stage exploration projects to spin out/farm out or sell. The strategy is initially focussed on Southern and Central Africa, and good opportunities will occur in countries with relatively stable and reliable political system such as Zambia. The Company has raised £1.05m before costs. The net proceeds of the Placing will be primarily applied for the development of the Group’s Njoka project and working capital. Admission is expected week commencing 21st February 2022.

Cleantech Lithium intends to join AIM. The Group is intending to produce lithium using a sustainable direct lithium extraction method, which returns water to its source instead of depleting vital aquifers. Each of the Projects are based in Chile, one of the world’s best regions for solar and other renewable energy. The intention is to utilise renewable energy for process power. The result being that the overall process will have a very low CO2 footprint potentially giving a critical advantage in the European Union market which has set strict CO2 emissions limits. Mkt Cap and Capital to be raised TBC. Due 14 March 2022.

GCP Co-Living REIT plc, intends to float on the Main Market. The Company is a newly established, externally managed investment company, which it is intended will carry on business as a Real Estate Investment Trust, subject to meeting the necessary qualifying conditions. The Company will invest, predominantly, in independent Co-Living Asset, both operational and under development, let to a diversified mix of residents, located in urban centres in the UK and Ireland where there is a shortage of high quality, affordable residential accommodation. Due March 2022.

Spinnaker Acquisitions plc, intends to join the Main Market (Standard). The Company have conditionally agreed to acquire the entire issued share capital of HomeServe Labs Ltd, a wholly owned subsidiary of FTSE250 quoted public company HomeServe Plc, by way of a reverse takeover conditional, inter alia on relisting and successful completion of fundraising activities to be undertaken by way of a placing and direct subscriptions by new and existing investor. If the Proposed Transaction proceeds to completion, it is proposed to change the name of the Company to Ondo InsurTech Plc and the name of Labs, which will become a subsidiary of the Company, to LeakBot Ltd. Should the Proposed Transaction not proceed, then the Company would need to apply for the suspension of its listing of ordinary shares to be lifted and for trading to be restored. £5m capital to be raised. Due early 2022.

Carbon Air, a nano-technology company which leverages the adsorption properties of activated carbon and other advanced materials to improve suspension systems, enhance acoustics or reduce noise, to join AIM. The Company’s proprietary technology has allowed it to develop a unique portfolio of solutions for a variety of sizeable end markets, including vehicle suspension systems, acoustic insulation for domestic appliances and micro-speakers for smartphones. Mkt Cap and Capital to be raised TBC. Due Late March.

Spiritus Mundi due to join the Main Market (Standard), a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector. The Company has already raised approximately £1.2m in a pre-IPO fundraising round. Delayed until second half of Q1 2022.

Recycling Tech Group to join AIM, a UK-based engineering, research and manufacturing company that has developed a modular and mass producible machine, the RT7000, which processes hard to recycle plastic waste into a synthetic oil that can be sold back to the petrochemicals industry as a chemical feedstock to make new plastics. Targeting a £40m raise. Due early March 2022.

Nu-Oil and Gas to acquire Guardian Maritime Ltd and Guardian Barriers IP Ltd and become Guardian Global Security plc and join the Main Market (Standard). Guardian is a technology group that supplies products to prevent unauthorised entry into areas that are deemed to have value, with maritime security being the main focus initially. Due Feb.


Breakfast Buffet

7Digital Group 0.375p £10.2m (7DIG.L)

The global leader in B2B end-to-end digital music solutions, announced that the Company has signed a contract with an existing B2B music streaming service customer, worth a minimum of EUR2.2m over a three-year period. The Company has been providing services to the customer since 2016, with contract renewals on an annual basis. This latest contract expands the relationship to a long-term agreement, providing greater visibility over revenue. The Company also expects the value of the contract to increase as the fast-growing customer seeks to expand its brand into further territories, which would require further licence agreements with 7digital. Under the terms of the contract, the customer will use 7digital’s extensive music catalogue to provide on-demand streaming services for brands and businesses as well as playlisting curation capability using fully licensed music.

AFC Energy 38p £279.5m (AFC.L)

Update on the status of the Company’s fuel cell field deployment in Spain with partner, ACCIONA. ACCIONA and AFC Energy have agreed to field deploy the Company’ first Hybrid Fuel Cell (HFC) system in Spain at a construction site north of Cadiz. The decision follows an update on AFC Energy’s product roadmap presented to ACCIONA in November 2021. The HFC system, announced as a new product line in December 2021 by AFC Energy, offers materially higher energy density versus the L Series that was initially proposed for deployment with ACCIONA. AFC Energy is currently building the first HFC system in the UK where it expects to be factory commissioned before being shipped to Spain. The field deployment of the HFC system is part of ACCIONA’s commitment to decarbonise its global portfolio of construction sites. The terms of the field deployment will mirror the cost sharing arrangements of the prior L Series demonstration which this now replaces.

Barkby Group 15p £20.5m (BARK.L)

Rupert Fraser will step down from the Board of Directors and the position of Group Managing Director of the Company with immediate effect. Rupert will remain with the Company and will assume the role of Managing Director of Barkby Pub Co. Ltd. Charles Dickson, Chairman of Barkby, said : “The Board and I would like to thank Rupert for his significant contribution to the Board and the group as whole. This new role will allow Rupert to focus exclusively on delivering the important growth plans of our pub business.” Barkby is a diverse portfolio of businesses providing services and products to meet current and future needs, within evolving markets.

Beowulf Mining 13.5p £112.3m (BEM.L)

The Company has invested a further £200k in Vardar Minerals Ltd. The investment increases the Company’s ownership in Vardar from 49.4 per cent to approximately 51.4 per cent, a majority shareholding. Kurt Budge, Chief Executive Officer of Beowulf, commented: “I am very pleased to make this investment in Vardar, which gives Beowulf a majority shareholding in the company and is made in readiness for the next drilling campaign. With plans to drill 3,400 metres, into lead-zinc targets at Wolf Mountain, gold targets at Majdan Peak and a lithium target at Viti, and extensive geophysical surveys over the newly acquired Shala licence, we are looking forward to a busy few months in Kosovo.”

Deepmatter Group 0.25p £9.5m (DMTR.L)

The international digital chemistry data company, has signed a licensing and collaboration agreement with Standigm Inc., a leading workflow artificial intelligence (AI) drug discovery company, based in South Korea with an increasing international footprint. The first stage of the agreement is expected to generate revenues of £233k. The Group is now actively working towards broadening the scope of the agreement in the three-year term. DeepMatter will provide access to its proprietary data and algorithms via its unique data and laboratory integration platform. This will enable Standigm to be more efficient and productive in its drug discovery programmes through deeper data insights and analysis. DeepMatter and Standigm will collaborate to develop further AI-driven drug discovery capabilities, drawing upon the Group’s deep digital chemistry expertise.

FD Technologies 1,870p £521.7m (FDP.L)

The Company has entered into a strategic partnership agreement with Microsoft to expand the reach of its KX Insights streaming data analytics platform as more organisations look to modernise their data infrastructure for real-time decision making. Firstly, KX Insights will be embedded natively on the Microsoft Azure platform as a first class service, with KX generating revenue based on consumption. Secondly, KX has agreed to work with Microsoft to target new applications and services that will accelerate innovation and growth for organisations in the financial services sector.

Journeo 103.5p £9m (JNEO.L)

The provider of information systems and technical services to transport operators and local authorities, has received a £2.1m purchase order from the City of Edinburgh to upgrade its real-time outdoor passenger display systems estate. The purchase order includes the supply and support of over 400 optically bonded new displays as part of the second phase of a 5 year £4.8m services and support contract originally announced by the Company in December 2019 and follows completion of the initial £0.8m purchase order for the supply of integrated real-time passenger systems and software for Edinburgh bus station, announced on 27 January 2020. The new displays will be installed at bus stops and bus shelters throughout the City of Edinburgh delivering multiple benefits, including higher contrast and greater readability in all light-levels with lower energy consumption, whilst providing the travelling public with more feature-rich information such as departure-specific disruption messaging. The Company expects to deliver £1.2m of the project this financial year ending 31 December 2022, paving the way for the City of Edinburgh Council to investigate potential new sites to further expand their real-time estate.

Lords Group Trading 99p £156.9m (LORD.L)

Lords, a leading distributor of building materials in the UK, has acquired the business and assets of a leading local independent builders merchant, A.W. Lumb through the acquisition of the entire issued share capital of AWLC Limited for a total consideration of £23.1m. The Acquisition is in line with Lords’ stated strategy at the time of IPO in July 2021. The Acquisition is to be immediately earnings accretive. Total Acquisition consideration of £23.1m, payable in cash, consists of £19.5m due on completion and deferred consideration of £3.6m payable in equal annual instalments over the next five years. Consideration is to be funded from Lords’ existing cash resources and debt facilities. The Acquisition provides the Group with an extension of its product offering and geographical reach into the North of England. Both key senior management from A.W. Lumb and its 77 employees will be joining the Group, ensuring continuity of local knowledge and customer relationships, as well as continuing the family values core to Lords’ success. Established in 1964 and family owned until a management buyout in 2017, A.W. Lumb is a leading independent builders merchant operating in the North of England from depots in Dewsbury and Tamworth. A.W. Lumb has a general merchanting service, with offerings in building materials, garden landscaping, timber & joinery and roofing products. The business also provides a specialist offering in drylining and insulation to housebuilders. A.W. Lumb’s customers include several well-known house builders, civil engineering contractors, local authorities, plasterers and smaller developers. In the year to 30 June 2021, AWLC generated revenues of £43.3m, EBITDA of £3.9m and a profit before tax of £3.8m.

Mobile Streams 0.42p £10.8m (MOS.L)

Monthly revenue now exceeds $150k per month across all channels. This is an increase of 87.5% in monthly revenue since the Company’s update on 1 December 2021. Whilst the Company intends to report revenue figures on a quarterly basis going forward, it is pleased to note the growth in revenues at this stage. In addition, the Company has commenced the process of uploading its content, including Esports, to the Huawei App gallery and anticipates once successful these will be made available across the Huawei handset user base. The Streams Data business provides data insight, intelligence and visualisation services and marketing optimisation tools. The enterprise level bespoke service achieved first revenues in June 2020, and the Streams SaaS self-service platform generated initial customer revenues in October 2020. Enterprise clients include The Economist and Quanta Media Group.

Oncimmune 122p £109.75m (ONC.L)

The global immunodiagnostics group, announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker analytical and advisory services in translational and clinical research. Following an assessment of ImmunoINSIGHT’s competence and capability, Synexa Life Sciences has selected Oncimmune’s ImmunoINSIGHTS platform to provide its clients access to specialist autoantibody services. This collaborative partnership will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications. Both companies utilise technologies to identify biological signatures, leveraging their deep expertise in the immunological underpinnings of health and disease to improve patient diagnostics and therapeutics. Over the next 18 months, Synexa Life Sciences plans to sign multiple new contracts with their partners for autoantibody profiling acting to broaden and enhance ImmunoINSIGHT’s own business development efforts. This new strategic collaboration comes at a time when autoantibody profiling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial interest, with the market segment growing at approximately 27% year-upon-year.

1 March 2022
*A corporate client of Hybridan LLP

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2023 - Hybridan | Website by Boxed Up Media
First Visit
Legal Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram